In addition, the above results were verified in our clinical BC patients: with 77.87, 80.19, 69.04 and 81.49% reduction of mRNA expression of METTL3, METTL14, WTAP and FTO and 1.71-fold induction of ALKBH5 mRNA expression in tumor tissue as compared with non-tumor tissue (Fig. 2a-e). The gene discussed is ALKBH5; the disease is neoplasm.